Understand the source comparison
Quickcomparison
Dose Range Abarelix 100 mg–500 mg mg Degarelix 80 mg–240 mg mg Frequency Once daily Administration Intramuscular injection (depot formulation) As directed by healthcare provider Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Evidence Level St
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dose Range
- Abarelix
- 100 mg–500 mg mg
- Degarelix
- 80 mg–240 mg mg
- Frequency
- Once daily
- Administration
- Intramuscular injection (depot formulation)
- As directed by healthcare provider
- Cycle Length
- Ongoing/indefinite
- Onset Speed
- Moderate (1-2 weeks)
- Evidence Level
- Strong human trials (Phase 3 or FDA approved)
- Efficacy